Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer
Background Corticosteroids (CS) are the mainstay of immune-related adverse effect (irAE) management, as well as for other indications in cancer treatment. Previous studies evaluating whether CS affect immune checkpoint inhibitor (CPI) efficacy compared patients receiving CS versus no CS. However, th...
Main Authors: | Richa Goel, Zoe Blake, Daniel H Johnson, Karine Tawagi, Victoria Simenson, Helen Yuan, Cameron Parent, Adi Bamnolker, Diana V Maslov, Madhav KC, Marc R Matrana |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/7/e002261.full |
Similar Items
-
190 Timing of steroid doses and response rates to immune-checkpoint inhibitors in metastatic cancer
by: Richa Goel, et al.
Published: (2020-11-01) -
Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors
by: Guoqiang PAN, et al.
Published: (2019-12-01) -
Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
by: Melissa Lumish, et al.
Published: (2020-06-01) -
COVID-19 and Cold Agglutinin Hemolytic Anemia
by: Diana V. Maslov, et al.
Published: (2020-07-01) -
Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer
by: Liu ZB, et al.
Published: (2020-03-01)